Carl Zeiss Meditec AG
Other OTCTotal Valuation
Carl Zeiss Meditec AG carries a market capitalization of 2.92B, placing it among publicly traded companies globally. Its enterprise value stands at 3.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.92B |
| Enterprise Value | 3.37B |
Valuation Ratios
Carl Zeiss Meditec AG trades at a trailing price-to-earnings ratio of 27.92.
| PE Ratio | 27.92 |
| PS Ratio | 1.53 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | 13.32 |
| P/OCF Ratio | 13.32 |
Enterprise Valuation
On an enterprise value basis, Carl Zeiss Meditec AG trades at an EV/EBITDA multiple of 17.15 and an EV/FCF ratio of 12.36. The EV/Sales ratio of 1.53 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.15 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.53 |
| EV / EBITDA | 17.15 |
| EV / EBIT | 17.15 |
| EV / FCF | 12.36 |
Financial Position
Carl Zeiss Meditec AG maintains a current ratio of 4.38, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.25, indicating elevated leverage, while an interest coverage ratio of 7.23 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 4.38 |
| Quick Ratio | 0.13 |
| Debt / Equity | 13.25 |
| Debt / EBITDA | N/A |
| Interest Coverage | 7.23 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 18.51 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Carl Zeiss Meditec AG has paid 46.51M in income taxes, reflecting an effective tax rate of 27.62.
| Income Tax | 46.51M |
| Effective Tax Rate | 27.62 |
Stock Price Statistics
Carl Zeiss Meditec AG's stock has declined approximately -43.35368% over the past 52 weeks. The 50-day moving average sits at 30.88, while the 200-day moving average is 38.14.
| Beta (5Y) | N/A |
| 52-Week Price Change | -43.35368% |
| 50-Day Moving Average | 30.88 |
| 200-Day Moving Average | 38.14 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Carl Zeiss Meditec AG generated 2.20B in revenue and converted that into 120.62M in net income, yielding earnings per share of 1.44. EBITDA reached 196.36M, while operating income came in at 196.36M.
| Revenue | 2.20B |
| Gross Profit | 1.15B |
| Operating Income | 196.36M |
| Pretax Income | 168.40M |
| Net Income | 120.62M |
| EBITDA | 196.36M |
| EBIT | 196.36M |
| Earnings Per Share (EPS) | 1.44 |
Cash Flow
Carl Zeiss Meditec AG produced 252.86M in operating cash flow over the past twelve months.
| Operating Cash Flow | 252.86M |
| Capital Expenditures | N/A |
| Free Cash Flow | 252.86M |
| FCF Per Share | 3.00 |
Margins
Carl Zeiss Meditec AG operates with a gross margin of 52.19, reflecting its pricing power and cost economics. The operating margin of 8.91 and net profit margin of 5.47 provide insight into operational efficiency.
| Gross Margin | 52.19 |
| Operating Margin | 8.91 |
| Pretax Margin | 7.64 |
| Profit Margin | 5.47 |
| EBITDA Margin | 8.91 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 5.22 |
| FCF Yield | 7.51 |
Scores
Carl Zeiss Meditec AG posts an Altman Z-Score of 8.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.87 |